BioSpace News Archive

Stericycle, Inc., a leading provider of medical waste management, secure information destruction and patient engagement solutions, announced chief executive officer Cindy J. Miller has been named to the Forbes 50 Over 50 list.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute.

IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), today announced that it has entered into an exclusive distribution agreement with KTRFIOS IMPORTACAO E EXPORTACAO LTDA (the “Distributor”) to sell the Company’s ProSense™ Cryoablation System in Brazil,

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera.

Kimberly-Clark announced a partnership with the biotech company RWDC Industries to advance sustainable technology for consumer products that provides much-needed solutions to the world’s single-use plastics problem.

Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities

Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders and rare diseases, announced it has been granted Orphan Drug Designation for SPG302 in amyotrophic lateral sclerosis by the U.S. Food and Drug Administration.

Microbot Medical Inc. continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board.

Acepodia, today announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational research collaboration with the Kennedy Institute for Rheumatology and the Sir William Dunn School of Pathology, University of Oxford.